Can Bausch Health Companies cover its short-term obligations?

Its current ratio is 1.32 — current assets exceed current liabilities.

Where does Bausch Health Companies's balance sheet data come from?

Every line is extracted from Bausch Health Companies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Bausch Health Companies BHC Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$1.33B+10.3%	$1.2B+24.8%	$962M+62.8%	$591M-72.1%
Restricted cash	$16M-20.0%	$20M+33.3%	$15M-44.4%	$27M—
Raw materials	$564M+4.4%	$540M+6.1%	$509M+56.1%	$326M—
Work in process	$102M-5.6%	$108M-12.9%	$124M+26.5%	$98M—
Finished goods	$963M+1.7%	$947M+4.0%	$911M+36.8%	$666M—
Total current assets	$6.16B+6.6%	$5.77B+3.2%	$5.6B+31.8%	$4.25B-24.3%
Property and equipment, net	$2.07B+16.5%	$1.78B+4.3%	$1.71B+6.7%	$1.6B+0.1%
Accumulated depreciation	$24.41B+4.7%	$23.31B+3.5%	$22.51B+5.5%	$21.33B—
Goodwill	$11.27B+1.7%	$11.09B-0.9%	$11.18B-3.2%	$11.55B-7.3%
Intangible assets, net	$2.85B-48.7%	$5.55B-14.0%	$6.46B+11.3%	$5.8B-16.5%
Other non-current assets	$378M+4.1%	$363M+18.2%	$307M-5.8%	$326M-4.1%
Total assets	$26.37B-0.6%	$26.52B-3.0%	$27.35B+6.5%	$25.69B-12.0%
Accounts payable	$600M+1.9%	$589M-18.1%	$719M+38.0%	$521M+28.0%
Accrued expenses	$3.34B-4.2%	$3.49B+11.4%	$3.13B+4.9%	$2.99B-37.6%
Accrued compensation	$385M+10.6%	$348M-3.3%	$360M+20.0%	$300M—
Current portion of long-term debt	$225M-91.6%	$2.67B+494%	$450M+4.2%	$432M—
Income taxes payable	$38M-39.7%	$63M+34.0%	$47M+56.7%	$30M—
Accrued interest	$253M+16.6%	$217M-8.1%	$236M+13.5%	$208M—
Total current liabilities	$4.18B-38.1%	$6.75B+57.0%	$4.3B+9.2%	$3.94B-24.2%
Deferred tax liabilities	$147M+14.8%	$128M-21.5%	$163M-19.3%	$202M-61.8%
Long-term debt	$20.59B+8.7%	$18.94B-13.7%	$21.94B+7.9%	$20.33B-10.2%
Other non-current liabilities	$793M+11.2%	$713M-8.1%	$776M+4.7%	$741M+13.5%
Total liabilities	$25.99B-3.2%	$26.85B-2.1%	$27.43B+7.9%	$25.43B-13.0%
Common stock	$10.52B+0.2%	$10.49B+0.6%	$10.42B+0.3%	$10.39B+0.7%
Additional paid-in capital	$357M+52.6%	$234M+9.3%	$214M+34.6%	$159M-65.6%
Retained earnings	-$9.67B+1.6%	-$9.82B-0.5%	-$9.78B-6.4%	-$9.19B-2.5%
Accumulated other comprehensive income (loss)	-$1.76B+19.2%	-$2.18B-15.8%	-$1.88B+8.5%	-$2.06B-6.9%
Noncontrolling interests	$931M-2.7%	$957M+1.8%	$940M-1.3%	$952M+1,222%
Total stockholders' equity	-$554M+56.7%	-$1.28B-25.1%	-$1.02B-47.7%	-$692M-553%
Total liabilities and stockholders' equity	$26.37B-0.6%	$26.52B-3.0%	$27.35B+6.5%	$25.69B-12.0%
Allowance for Doubtful Accounts	$31M+3.3%	$30M-11.8%	$34M+3.0%	$33M-5.7%
Allowance for Doubtful Accounts Receivable (Current)	$31M+3.3%	$30M-11.8%	$34M+3.0%	$33M-5.7%
Accumulated Goodwill Impairment Losses	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$378M+4.1%	$363M+18.2%	$307M-5.8%	$326M-4.1%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	——	——	——	——
Finite Lived Intangible Assets - Gross	$27.25B+0.7%	$27.06B-0.7%	$27.26B+7.2%	$25.44B—
Intangible Assets Gross (Excluding Goodwill)	$29.05B+0.7%	$28.86B-0.4%	$28.97B+6.7%	$27.13B—
Deferred tax assets	$1.84B-6.4%	$1.97B-6.3%	$2.1B-3.0%	$2.17B-3.8%
Intangible assets — net	$2.85B-24.2%	$3.75B-21.0%	$4.75B+15.9%	$4.1B—
Other intangible assets—net	$4.64B-16.4%	$5.55B-14.0%	$6.46B+11.3%	$5.8B-16.5%
Other non-current assets	$378M+4.1%	$363M+18.2%	$307M-5.8%	$326M-4.1%
Property, plant and equipment, net	$2.07B+16.5%	$1.78B—	——	——
Software and Technology Licenses, Net	$378M+4.1%	$363M+18.2%	$307M-5.8%	$326M-4.1%
Tax Credit Carryforward Valuation Allowance	$2.58B+12.8%	$2.28B+1.3%	$2.25B+2.5%	$2.2B—
Other Commercial Liabilities	$3.34B-4.2%	$3.49B+11.4%	$3.13B+4.9%	$2.99B-37.6%
Accrued Income Taxes, Current	$38M-39.7%	$63M+34.0%	$47M+56.7%	$30M—
Accrued Liabilities, Current	$3.34B-4.2%	$3.49B+11.4%	$3.13B+4.9%	$2.99B-37.6%
Financial leases	$11M—	$0—	——	——
Short-Term Debt - Weighted-Average Interest Rate	8.5%+0.8%	7.7%-0.3%	8.1%+0.3%	7.7%—
Contingent Consideration Liability (Non-Current)	——	——	——	——
Debt Maturity - 2024	——	——	——	——
Debt Maturity - 2027	——	——	——	——
Debt Maturity - Thereafter	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	——	——	——	——
Acquisition-related contingent consideration	$254M-18.1%	$310M+22.5%	$253M+21.6%	$208M+3.0%
Non-current portion of financial leases	$23M—	$0—	——	——
Total debt	$21.05B-3.6%	$21.84B-3.4%	$22.6B+7.6%	$21B-8.4%
Total Carrying Value of Debt	$20.23B-1.2%	$20.48B-2.5%	$21.01B+9.9%	$19.11B—
Unrecognized Tax Benefits - Impacting Effective Tax Rate	——	——	——	——
Unrecognized Tax Benefits - Income Tax Penalties and Interest Accrued	$68M0.0%	$68M+33.3%	$51M+59.4%	$32M—
Common Stock Shares Issued	370.5M+0.7%	367.8M+0.7%	365.2M+0.9%	361.9M—
Cumulative Gross Losses and Impairments	——	——	——	——
Additional paid-in capital	$357M+52.6%	$234M+9.3%	$214M+34.6%	$159M-65.6%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$10.52B+0.2%	$10.49B+0.6%	$10.42B+0.3%	$10.39B+0.7%
Fair Value Measurement Disclosure	$292M-18.7%	$359M+22.9%	$292M+21.2%	$241M0.0%
Number of Countries of Operation	——	——	——	——
Product rebates	$1.32B-4.6%	$1.39B+29.6%	$1.07B+8.7%	$983M—
Product returns	$348M-6.5%	$372M-2.1%	$380M-11.0%	$427M—
Accounts Receivable, Allowance for Credit Loss	$31M+3.3%	$30M-11.8%	$34M+3.0%	$33M-5.7%
Acquisition-related contingent consideration	$292M—	——	——	——
Common stock, shares issued (in shares)	$370.53M+0.7%	$367.84M+0.7%	$365.24M+0.9%	$361.9M—
Common Stock, Shares, Outstanding	$370.53M+0.7%	$367.84M+0.7%	$365.24M+0.9%	$361.9M—
Long-term debt, gross	$20.23B-1.2%	$20.48B-2.5%	$21.01B+9.9%	$19.11B—
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	——	——	——	——
Weighted Average Interest Rate (as a percent)	$0.09+10.6%	$0.08-4.1%	$0.08+4.0%	$0.08—
Deferred income taxes	$147M+14.8%	$128M-21.5%	$163M-19.3%	$202M-61.8%
Deferred Tax Assets, Valuation Allowance	$2.58B+12.8%	$2.28B+1.3%	$2.25B+2.5%	$2.2B—
Finite-Lived Intangible Assets, Accumulated Amortization	$24.41B+4.7%	$23.31B+3.5%	$22.51B+5.5%	$21.33B—
2028	——	——	——	——
2030	——	——	——	——
2031	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Five	——	——	——	——
Gross Carrying Amount	$27.25B+0.7%	$27.06B-0.7%	$27.26B+7.2%	$25.44B—
Goodwill accumulated impairment losses	——	——	——	——
Indefinite- lived intangible impairment	$29.05B+0.7%	$28.86B-0.4%	$28.97B+6.7%	$27.13B—
Raw materials	$564M+4.4%	$540M+6.1%	$509M+56.1%	$326M—
Legal matters and related fees	$178M-46.4%	$332M—	——	——
2028	——	——	——	——
2029	——	——	——	——
2029	——	——	——	——
2030	——	——	——	——
Thereafter	——	——	——	——
2027	——	——	——	——
Remainder of 2026	——	——	——	——
Noncontrolling interests in subsidiaries	$931M-2.7%	$957M+1.8%	$940M-1.3%	$952M+1,222%
Number of countries in which Visa operates (more than)	——	——	——	——
Other accrued liabilities	$821M+6.3%	$772M+10.8%	$697M-2.4%	$714M—
Proceeds from sale of loans to third-party investors	——	——	——	——
Unrecognized tax benefits including interest and penalties	$914M-1.1%	$924M+0.7%	$918M+4.2%	$881M—
Penalties and interest accrued on unrecognized tax benefits	$68M0.0%	$68M+33.3%	$51M+59.4%	$32M—
Amount that if recognized, would affect the effective tax rate or regulatory liability	——	——	——	——
Valuation Allowances And Reserves Balance	$2.06B-7.8%	$2.24B+15.4%	$1.94B+1.5%	$1.91B+2.5%
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Bausch Health Companies cover its short-term obligations?: Its current ratio is 1.32 — current assets exceed current liabilities.
Where does Bausch Health Companies's balance sheet data come from?: Every line is extracted from Bausch Health Companies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.